FDA Import Refusal AEK-1379770-7/21/1 — AstraZeneca Pharmaceuticals LP
The FDA refused shipment AEK-1379770-7/21/1 from AstraZeneca Pharmaceuticals LP (United States) on Jul 6, 2022. The refused product falls under Drugs and Biologics — DAPAGLIFLOZIN (ANTI-DIABETIC). Cited charge: 75 This firm has 5 or more other import refusals on record.
Refusal Details
- Date
- Jul 6, 2022
- Country
- United States
- Product Category
- Drugs and Biologics
- Product Code
- 61PCY70 DAPAGLIFLOZIN (ANTI-DIABETIC)
- Charges
- 75